H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Cabaletta Bio to $15 from $11 and keeps a Buy rating on the shares. During the last couple of months, Cabaletta has shifted focus from its Chimeric AutoAntibody Receptor T program to the most recent addition to its portfolio, CABA-201, a Chimeric Antigen Receptor T cell for Autoimmunity candidate, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CABA:
- 3 Stocks to Buy Today, 3/17/2023, According to Top Analysts
- Cabaletta Bio reports Q4 EPS (52c), consensus (45c)
- Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
